.png)
Board Agenda: The Macro Memo
The Macro Memo is an essential briefing for UK corporate leaders, offering timely insights into the geopolitical and macro-economic forces shaping today’s business environment. Produced by Board Agenda, the corporate goverrnance news and intelligence resource, this podcast series is published in association with Forvis Mazars, the global auditing, accounting and advisory business. In each episode, we explore the impact of global trends, from economic policies to political shifts, and how they translate into risks and opportunities for businesses. Stay ahead of the curve with The Macro Memo—your guide to understanding the global factors that drive local business strategy.
Board Agenda: The Macro Memo
What’s next for boards in the UK pharma and life sciences industry? Navigating the challenges of innovation, productivity and ESG in a post Covid world.
What’s next for boards in the UK pharma and life sciences industry? Navigating the challenges of innovation, productivity and ESG in a post Covid world.
The life science industry is in a dynamic phase of transformation which has been rapidly accelerated by the pandemic, with more workforce agility, shortening development and review times, increased speed to market, and greater efficiencies. In response to the pandemic, life sciences companies mobilized impressively to meet the needs of their employees, patients, customers, and communities. This mobilization, however, has upended well-established business norms, including about how and where people work.
panel guests discuss.
- Key priorities for boards in life sciences industry as they transition to the future of healthcare
- Harnessing opportunities from rapid digitalisation and tech disruption
- Building resilience in an era of rapid transformation
- Ideal skill sets and composition of life science company boards
- How boards in pharma and life science are integrating ESG and building trust with stakeholders
